Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis
